Agomelatine improves symptoms of generalised anxiety disorder
Baldwin, David S. and Lopes, Antonio T. (2009) Agomelatine improves symptoms of generalised anxiety disorder. Evidence-Based Mental Health, 12, (2), 54-54. (doi:10.1136/ebmh.12.2.54 ).
Full text not available from this repository.
Is agomelatine effective for people with generalised anxiety disorder?
121 people, aged 18–65 years, with DSM-IV generalised anxiety disorder (69% female, mean age 42 years) (see online notes for exclusion criteria).
Five centres in Finland and six centres in South Africa; time period not stated.
Agomelatine (n = 63; 25–50 mg/day) or placebo (n = 58) for 12 weeks. Agomelatine dose was increased from 25 to 50 mg/day if there was an insufficient response after 2 weeks. This was done in a blinded fashion, using a dose adjustment algorithm.
Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (≥50% reduction in HAM-A score); somatic anxiety, psychic anxiety, severity of illness, sleep and disability symptoms (HAM-A subscales, Clinical Global Impressions Scale, Leeds Sleep Evaluation Questionnaire and Sheehan Disability Scale); discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS)).
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Clinical Neurosciences
University Structure - Pre August 2011 > School of Medicine
|Date Deposited:||27 Apr 2010 11:00|
|Last Modified:||27 Mar 2014 19:08|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)